Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

C0685000

Cefotaxime sodium

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Cefotaxime sodium salt, Cefotaxim sodium salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C16H16N5NaO7S2
Numéro CAS:
64485-93-4
Poids moléculaire :
477.45
Numéro Beilstein :
5711411
Numéro MDL:
MFCD00079073
Code UNSPSC :
41116107
ID de substance PubChem :
329774812
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

cefotaxime

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

[Na+].[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c3csc(N)n3)C([O-])=O

InChI

1S/C16H17N5O7S2.Na/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8;/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26);/q;+1/p-1/b20-9-;/t10-,14-;/m1./s1

Clé InChI

AZZMGZXNTDTSME-JUZDKLSSSA-M

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cefotaxime sodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Cefotaxim inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls. As a result, bacteria lyse due to cell wall autolytic enzymes.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Broad spectrum third generation cephalosporin antibiotic.
Sales restrictions may apply.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H317,H334

Classification des risques

Resp. Sens. 1 - Skin Sens. 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 5

1 of 5

Cefquinome sulfate VETRANAL®, analytical standard

Supelco

32472

Cefquinome sulfate

Ceftriaxone sodium European Pharmacopoeia (EP) Reference Standard

C0691000

Ceftriaxone sodium

Tazobactam sodium salt β-lactamase inhibitor

Sigma-Aldrich

T2820

Tazobactam sodium salt

Vancomycin hydrochloride European Pharmacopoeia (EP) Reference Standard

V0045000

Vancomycin hydrochloride

Cefoxitin sodium salt

Supelco

C4786

Cefoxitin sodium salt

Martijn F Schenk et al.
PLoS genetics, 8(6), e1002783-e1002783 (2012-07-05)
For a quantitative understanding of the process of adaptation, we need to understand its "raw material," that is, the frequency and fitness effects of beneficial mutations. At present, most empirical evidence suggests an exponential distribution of fitness effects of beneficial
Ryuichi Nakano et al.
Journal of medical microbiology, 61(Pt 12), 1727-1735 (2012-09-01)
Proteus mirabilis is a common cause of urinary tract infection. Wild-type P. mirabilis strains are usually susceptible to penicillins and cephalosporins, but occurrences of P. mirabilis producing extended-spectrum β-lactamases (ESBLs) have been recently reported. Here, we surveyed the prevalence of
I Mounchetrou Njoya et al.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 17(34) (2012-09-04)
In April 2012, a cluster of two cases of meningococcal disease caused by rifampicin-resistant C meningococci was reported in the Champagne-Ardenne region, France. The two cases occurred in a student population living in the same town but studying at different
Katrine Hartung Hansen et al.
Applied and environmental microbiology, 79(3), 794-798 (2012-11-20)
Current knowledge on extended-spectrum beta-lactamases (ESBLs) in animals is based largely on cross-sectional studies and qualitative data. The aim of this longitudinal study was to elucidate carriage proportions and fecal counts of ESBL-producing Escherichia coli in pigs during the production
Lakshmi Chandramohan et al.
Antimicrobial agents and chemotherapy, 56(9), 4765-4770 (2012-06-27)
Very little is known about the prevalence and composition of various types of extended-spectrum β-lactamases (ESBL) in pediatric patients. The aims of this study were the following: (i) to determine the prevalence of ESBLs among Enterobacteriaceae in a tertiary-care pediatric
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique